General Information:

Id: 3,890 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Fatty liver disease, nonalcoholic
Insulin resistance
Metabolic syndrome
Mammalia
review
Reference: Matikainen N and Taskinen MR(2012) Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes Curr Cardiol Rep 14: 721-731 [PMID: 22941588]

Interaction Information:

Comment Analysis of prospective outcome studies involving 170,000 subjects demonstrates a robust beneficial effect of statins in CHD prevention in subgroups with diabetes, elevated systolic blood pressure, low HDL-C, and elevated BMI which all are components of MetS.
Formal Description
Interaction-ID: 39327

drug/chemical compound

Statin

decreases_activity of

disease

Coronary artery disease

in subjects with diabetes, elevated systolic blood pressure, low HDL, and elevated BMI
Comment Data suggest that dual metabolic defects: 1) overproduction of large VLDL particles driven by liver fat, and 2) impaired catabolism of TRLs due to high apoCIII are needed to produce hypertriglyceridemia in MetS. Therefore, none of the current therapies are optimal to treat residual risk associated with diabetic dyslipidemia as they are not directly addressing these underlying defects. After about 20 years of clinical use of statins, the awareness of diabetogenic potential has raised the debate whether statins are justified or not, especially in the primary prevention in MetS subjects with already compromised glucose metabolism. A large meta-analysis of statin trials confirmed that indeed statin therapy is associated with increased glucose levels and new-onset diabetes. Studies demonstrate a dose-dependent effect, at least with atorvastatin and rosuvastatin.
Formal Description
Interaction-ID: 39328

drug/chemical compound

Statin

increases_activity of

Comment Statins are the most powerful agents to decrease plasma concentrations of LDL-C and apoB but their impact on plasma TG and HDL-C concentrations is less robust. Fibrates have been demonstrated to improve all components of diabetic dyslipidemia. Therefore, it would be rational to use fibrates as an add-on therapy on top of statins to reduce the residual risk in MetS and diabetes.
Formal Description
Interaction-ID: 39329

drug/chemical compound

Statin

increases_activity of

in blood plasma
Comment Statins are the most powerful agents to decrease plasma concentrations of LDL-C and apoB but their impact on plasma TG and HDL-C concentrations is less robust. Fibrates have been demonstrated to improve all components of diabetic dyslipidemia. Therefore, it would be rational to use fibrates as an add-on therapy on top of statins to reduce the residual risk in MetS and diabetes.
Formal Description
Interaction-ID: 39331

drug/chemical compound

Statin

decreases_activity of

phenotype

increased circulating apolipoprotein B level

in blood plasma
Comment Statins are the most powerful agents to decrease plasma concentrations of LDL-C and apoB but their impact on plasma TG and HDL-C concentrations is less robust. Fibrates have been demonstrated to improve all components of diabetic dyslipidemia. Therefore, it would be rational to use fibrates as an add-on therapy on top of statins to reduce the residual risk in MetS and diabetes.
Formal Description
Interaction-ID: 39332

drug/chemical compound

Statin

NOT affects_activity of

Comment Statins are the most powerful agents to decrease plasma concentrations of LDL-C and apoB but their impact on plasma TG and HDL-C concentrations is less robust. Fibrates have been demonstrated to improve all components of diabetic dyslipidemia. Therefore, it would be rational to use fibrates as an add-on therapy on top of statins to reduce the residual risk in MetS and diabetes.
Formal Description
Interaction-ID: 39334

drug/chemical compound

Statin

NOT affects_activity of

Comment Even after the most effective statin therapy and despite aggressive lifestyle interventions, a substantial number of subjects with MetS or T2D remain at high residual risk and obviously require add-on lipid lowering therapy that should be based on individual risk-benefit assessment.
Formal Description
Interaction-ID: 39365

drug/chemical compound

Statin

NOT decreases_activity of

disease

Coronary artery disease

in part of the diabetic and metabolic syndrome patients, even in combination with intensive lifestyle intervention